- Denosumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2376998
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):8-17.
- doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Letter to the Editor
-
Park YK
- KMID: 2377004
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):59-59.
- doi: 10.1016/j.afos.2017.01.003
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Osteoporosis prevention and osteoporosis exercise in community-based public health programs
-
Nguyen VH
- KMID: 2376999
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):18-31.
- doi: 10.1016/j.afos.2016.11.004
Osteoporosis is a serious public health concern worldwide, and community-based public health programs that increase osteoporosis preventive behaviors are ideal to combat this major public health issue. A review of... -
- CITED
-
- Close
- SHARE
-
- Close
- Response to the Editor
-
Ohta H, Uenishi K, Shiraki M
- KMID: 2377005
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):60-61.
- doi: 10.1016/j.afos.2017.01.004
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Favorable effects of skeletal muscle on bone are distinguished according to gender and skeletal sites
-
Kim KM, Lee EY, Lim S, Jang HC, Kim CO
- KMID: 2377000
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):32-36.
- doi: 10.1016/j.afos.2016.11.001
OBJECTIVES: The aim of this study was to investigate associations between skeletal muscle mass and bone mineral density according to gender and skeletal sites. METHODS: Using the data from Korean National... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
-
Tanaka M, Nakamura Y, Itoh S, Kato Y
- KMID: 2377001
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):37-44.
- doi: 10.1016/j.afos.2016.12.002
OBJECTIVES: This is an open labeled and retrospective cohort study which compared the effectiveness and safety of ibandronate (IBN) and minodronate (MIN) combined with eldecalcitol (ELD) in primary osteoporosis of... -
- CITED
-
- Close
- SHARE
-
- Close
- An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015
-
Yeap SS, Hew FL, Damodaran , Chee W, Lee JK, Goh EM, Chan SP, The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2015
- KMID: 2376997
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):1-7.
- doi: 10.1016/j.afos.2017.01.001
OBJECTIVES: This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with glucocorticoid-induced osteoporosis (GIO), using the best available evidence. METHODS: A literature search using PubMed (MEDLINE)... -
- CITED
-
- Close
- SHARE
-
- Close
- Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
-
Nakatoh S
- KMID: 2377002
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):45-52.
- doi: 10.1016/j.afos.2016.12.001
OBJECTIVES: This study aimed to investigate the correlation between bone mineral density (BMD) and the turnover rate [√(MoMf²+ MoMr²), multiple of median formation (MoMf) was calculated as bone-specific alkaline phosphatase... -
- CITED
-
- Close
- SHARE
-
- Close
- Associations between serum 25-hydroxyvitamin D3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects
-
Kuwabara A, Tsugawa N, Kondo H, Ao M, Fujiwara H, Hosokawa N, Matsumoto , Tanaka K, Nakano T
- KMID: 2377003
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):53-58.
- doi: 10.1016/j.afos.2017.02.002
OBJECTIVES: One of the important risk factors of falling is decreased muscle mass and muscle strength. Recently, there has been an increasing concern on the role of vitamin D in... -
- CITED
-
- Close
- SHARE
-
- Close
